C-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycystic Kidney Disease Outcomes Consortium as a voting member. PKDOC brings together diverse stakeholders from the pharmaceutical industry, academic researchers, foundations, patient advocacy groups, individuals living with PKD, and regulatory agencies from around the world, to develop solutions to accelerate drug development for PKD, including biomarker endpoints and model-informed drug development tools.
The teams are excited to embark together on the consortium’s next chapter, PKDOC 2.0, with a focus on the development and regulatory endorsement of a clinical trial simulator tool, identification of novel fluid biomarkers, and development of patient reported outcome measures.
Join us in welcoming OPDC as PKDOC continues to carry out its mission to improve the lives of individuals living with PKD.
